clinical trial · NCT04286607
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Chronic Plaque PsoriasisTopical roflumilast
brief summary
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis
started
Feb 12, 2020
primary completion
Jan 22, 2024
completion
Jan 22, 2024
last updated
Jan 7, 2025
detailed description
This is an open-label study in which ARQ-151 cream is applied once daily x 24 weeks to subjects with psoriasis
official title
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol